scholarly journals Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Malaney R. O’Connell ◽  
Shubhashish Sarkar ◽  
Gurinder K. Luthra ◽  
Yoshinaga Okugawa ◽  
Yuji Toiyama ◽  
...  
Keyword(s):  
Human Colon ◽  
Clinical Implications ◽  
Epigenetic Changes ◽  
Colon Cancers ◽  
Alternate Promoter ◽  
Promoter Usage

Fibroblastic reaction and vascular maturation in human colon cancers

2009 ◽  
Vol 85 (11) ◽  
pp. 1013-1025 ◽  
Author(s):  
Stephan A. Schmid ◽  
Antje Dietrich ◽  
Stephanie Schulte ◽  
Andreas Gaumann ◽  
Leoni A. Kunz-Schughart
Keyword(s):  
Human Colon ◽  
Colon Cancers ◽  
Vascular Maturation

scholarly journals Trypsinogen Expression in Human Colon Cancers

2000 ◽  
Vol 25 (4) ◽  
pp. 624-630
Author(s):  
Katsunobu OYAMA ◽  
Tetsuo OHTA ◽  
Genichi NISHIMURA ◽  
Sachio FUSHIDA ◽  
Itasu NINOMIYA ◽  
...  
Keyword(s):  
Human Colon ◽  
Colon Cancers

Human Colon Cancers Recognize N-Carboxymethyl Gastrin by a Non-CCK1, Non-CCK2 Receptor

2001 ◽  
pp. 905-906 ◽  
Author(s):  
Felicitas I. Wibowo ◽  
Shawn Ahmed ◽  
Dmitry S. Gembitsky ◽  
Sándor Lovas ◽  
Richard F. Murphy
Keyword(s):  
Human Colon ◽  
Colon Cancers ◽  
Cck2 Receptor

scholarly journals Lemongrass Extract Possesses Potent Anticancer Activity Against Human Colon Cancers, Inhibits Tumorigenesis, Enhances Efficacy of FOLFOX, and Reduces Its Adverse Effects

2019 ◽  
Vol 18 ◽  
pp. 153473541988915 ◽  
Author(s):  
Ivan Ruvinov ◽  
Christopher Nguyen ◽  
Benjamin Scaria ◽  
Caleb Vegh ◽  
Ola Zaitoon ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Human Colon ◽  
Dependent Manner ◽  
Anticancer Efficacy ◽  
Colon Cancers ◽  
Induced Apoptosis

Current chemotherapeutics for metastatic colorectal cancers have limited success and are extremely toxic due to nonselective targeting. Some natural extracts have been traditionally taken and have shown anticancer activity. These extracts have multiple phytochemicals that can target different pathways selectively in cancer cells. We have shown previously that lemongrass ( Cymbopogon citratus) extract is effective at inducing cell death in human lymphomas. However, the efficacy of lemongrass extract on human colorectal cancer has not been investigated. Furthermore, its interactions with current chemotherapies for colon cancer is unknown. In this article, we report the anticancer effects of ethanolic lemongrass extract in colorectal cancer models, and importantly, its interactions with FOLFOX and Taxol. Lemongrass extract induced apoptosis in colon cancer cells in a time and dose-dependent manner without harming healthy cells in vitro. Oral administration of lemongrass extract was well tolerated and effective at inhibiting colon cancer xenograft growth in mice. It enhanced the anticancer efficacy of FOLFOX and, interestingly, inhibited FOLFOX-related weight loss in animals given the combination treatment. Furthermore, feeding lemongrass extract to APCmin/+ transgenic mice led to the reduction of intestinal tumors, indicating its preventative potential. Therefore, this natural extract has potential to be developed as a supplemental treatment for colorectal cancer.

scholarly journals O-GlcNAcylation of PGK1 coordinates glycolysis and TCA cycle to promote tumor growth

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Hao Nie ◽  
Haixing Ju ◽  
Jiayi Fan ◽  
Xiaoliu Shi ◽  
Yaxian Cheng ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cancer Cells ◽  
Tumor Development ◽  
Lactate Production ◽  
Phosphoglycerate Kinase ◽  
Tca Cycle ◽  
Human Colon ◽  
Colon Cancers ◽  
The Tca Cycle ◽  
Promote Tumor Growth

AbstractMany cancer cells display enhanced glycolysis and suppressed mitochondrial metabolism. This phenomenon, known as the Warburg effect, is critical for tumor development. However, how cancer cells coordinate glucose metabolism through glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle is largely unknown. We demonstrate here that phosphoglycerate kinase 1 (PGK1), the first ATP-producing enzyme in glycolysis, is reversibly and dynamically modified with O-linked N-acetylglucosamine (O-GlcNAc) at threonine 255 (T255). O-GlcNAcylation activates PGK1 activity to enhance lactate production, and simultaneously induces PGK1 translocation into mitochondria. Inside mitochondria, PGK1 acts as a kinase to inhibit pyruvate dehydrogenase (PDH) complex to reduce oxidative phosphorylation. Blocking T255 O-GlcNAcylation of PGK1 decreases colon cancer cell proliferation, suppresses glycolysis, enhances the TCA cycle, and inhibits tumor growth in xenograft models. Furthermore, PGK1 O-GlcNAcylation levels are elevated in human colon cancers. This study highlights O-GlcNAcylation as an important signal for coordinating glycolysis and the TCA cycle to promote tumorigenesis.

Sign in / Sign up

Export Citation Format

Share Document